Table 3.
Effect of HAART, HAART with protease inhibitor (PI), and HAART with nonnucleoside reverse-transcriptase inhibitor (NNRTI) initiation on mean CD4+ cell percentage, compared with noninitiation of HAART, overall and by CD4+ cell percentage at baseline.
| Difference in mean CD4+ cell percentage between patients with HAART initiation and patients without HAART intiation (95% CI) | ||||
|---|---|---|---|---|
| Variable | After 1 year of HAART |
After 2 years of HAART |
After 3 years of HAART |
After 5 years of HAART |
| HAART | 2.34 (1.35–3.33) | 3.32 (1.87–4.77) | 3.68 (2.04–5.32) | 4.42 (2.09–6.76) |
| All age groups | ||||
| CD4+ cell percentage <15% | 4.44 (2.27–6.62) | 7.96 (5.71–10.22) | 7.22 (4.61–9.83) | 8.93 (4.94–12.91) |
| CD4+ cell percentage 15%–24% | 2.78 (1.52–4.03) | 5.26 (3.03–7.49) | 4.39 (2.37–6.42) | 5.55 (3.18–7.91) |
| CD4+ cell percentage ⩾25% | 1.19 (0.01–2.38) | 0.39 (−1.12 to 1.90) | 2.12 (0.26–3.98) | 2.31 (−0.36 to 4.98) |
| Age <5 years | ||||
| CD4+ cell percentage <15% | 6.59 (1.76–11.42) | 10.61 (5.89–15.33) | 11.89 (6.69–17.08) | 6.85 (−3.53 to 17.23) |
| CD4+ cell percentage 15%–24% | 3.84 (1.29–6.39) | 6.07 (2.97–9.18) | 3.94 (0.76–7.12) | 4.32 (0.82–7.82) |
| CD4+ cell percentage ⩾25% | 0.77 (−0.95 to 2.49) | −0.33 (−2.42 to 1.76) | 2.53 (−0.24 to 5.29) | 4.47 (0.87–8.08) |
| Age ⩾5 years | ||||
| CD4+ cell percentage <15% | 3.72 (1.22–6.22) | 7.06 (4.42–9.69) | 5.74 (2.82–8.66) | 9.39 (5.15–13.64) |
| CD4+ cell percentage 15%–24% | 2.29 (0.80–3.77) | 4.89 (2.03–7.75) | 4.59 (2.16–7.03) | 6.10 (3.44–8.77) |
| CD4+ cell percentage ⩾25% | 1.46 (0.09–2.84) | 0.84 (−0.88 to 2.55) | 1.85 (−0.08 to 3.79) | 0.69 (−2.15 to 3.52) |
| HAART with PI | 2.70 (1.62–3.78) | 3.59 (2.14–5.03) | 4.45 (2.66–6.24) | 4.23 (1.56–6.90) |
| All age groups | ||||
| CD4+ cell percentage <15% | 5.34 (2.87–7.82) | 9.94 (7.33–12.56) | 8.10 (4.96–11.25) | 9.84 (5.25–14.43) |
| CD4+ cell percentage 15%–24% | 3.32 (1.95–4.68) | 4.98 (3.16–6.80) | 6.12 (3.92–8.33) | 6.04 (3.24–8.83) |
| CD4+ cell percentage ⩾25% | 1.22 (−0.06 to 2.51) | 0.78 (−0.86 to 2.43) | 2.67 (0.64–4.70) | 1.78 (−1.46 to 5.03) |
| Age <5 years | ||||
| CD4+ cell percentage <15% | 6.93 (1.58–12.29) | 14.55 (9.67–19.43) | 12.86 (6.85–18.88) | 10.29 (−2.50 to 23.08) |
| CD4+ cell percentage 15%–24% | 4.17 (1.58–6.76) | 6.23 (2.87–9.58) | 5.41 (1.82–9.00) | 4.35 (0.22–8.48) |
| CD4+ cell percentage ⩾25% | 0.70 (−1.15 to 2.55) | 0.16 (−2.12 to 2.44) | 3.29 (0.27–6.31) | 4.06 (0.04–8.07) |
| Age⩾ 5 years | ||||
| CD4+ cell percentage <15% | 4.78 (1.82–7.73) | 8.27 (5.18–11.36) | 6.40 (2.81–10.00) | 9.70 (5.29–14.10) |
| CD4+ cell percentage 15%–24% | 2.92 (1.29–4.56) | 4.41 (2.28–6.53) | 6.42 (3.80–9.04) | 6.74 (3.47–10.00) |
| CD4+ cell percentage ⩾25% | 1.59 (0.07–3.11) | 1.20 (−0.70 to 3.09) | 2.23 (0.10–4.36) | 0.10 (−3.82 to 4.02) |
| HAART with NNRTI | 2.82 (1.26–4.38) | 4.05 (1.74–6.36) | 5.61 (3.26–7.96) | 6.61 (2.75–10.48) |
| All age groups | ||||
| CD4+ cell percentage <15% | 7.65 (4.21–11.08) | 13.23 (9.02–17.43) | 12.10 (6.32–17.89) | 9.76 (0.56–18.95) |
| CD4+ cell percentage 15%–24% | 4.31 (2.10–6.52) | 6.10 (2.05–10.14) | 7.10 (3.05–11.14) | 10.29 (6.46–14.13) |
| CD4+ cell percentage ⩾25% | 0.30 (−1.52 to 2.13) | 0.71 (−1.55 to 2.97) | 3.55 (1.10–6.00) | 3.88 (−1.31 to 9.08) |
| Age <5 years | ||||
| CD4+ cell percentage <15% | 11.41 (3.35–19.47) | 13.93 (4.37–23.49) | 21.35 (10.56–32.15) | 11.73 (8.65–14.81) |
| CD4+ cell percentage 15%–24% | 4.96 (0.08–9.84) | 3.51 (−4.70 to 11.71) | 6.15 (−2.02 to 14.32) | 7.30 (−0.25 to 14.85) |
| CD4+ cell percentage ⩾25% | −0.45 (−3.42 to 2.51) | −1.12 (−4.44 to 2.20) | 5.19 (1.65–8.74) | 7.02 (3.82–10.22) |
| Age< 5 years | ||||
| CD4+ cell percentage <15% | 6.44 (2.76–10.11) | 12.85 (8.84–16.87) | 10.00 (4.20–15.81) | 9.29 (−1.85 to 20.43) |
| CD4+ cell percentage 15%–24% | 4.03 (1.42–6.63) | 7.27 (2.45–12.08) | 7.56 (2.79–12.34) | 12.19 (8.23–16.14) |
| CD4+ cell percentage ⩾25% | 0.79 (−1.43 to 3.01) | 1.99 (−0.58 to 4.56) | 2.48 (−0.24 to 5.19) | 1.62 (−6.00 to 9.23) |